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patients (16,7%) had previous PTMC, quarter of patients were in atrial
ﬁbrillation, all patients were symptomatic. Mitral valve area increased
from 1.05þ/-0.26 cm2 to 2.02þ/-0.45 cm2 (p<0.0001). Mean gradient
decreased from 13.52þ/-5.09 mmHg to 5.38 þ/- 3.15 mmHg (p<0.0001).
There was a signiﬁcant decrease in systolic pulmonary artery pressure
from 38.13þ/-7,55 mmHg to 28,25þ/-4.65mmHg (p¼0.006). Pulmonary
resistance measured by echocardiography using Tricuspid regurgita-
tion Vmax / Tricuspid VTI ratio dropped from 0.140þ/-0.017 to
0.116þ/- 0.015 (p¼0.023). Tricuspid annular point systolic excursion
(TAPSE) increased from 21.58þ/-3.08mm to 24.25þ/-4.80mm
(p¼0.029) then to 24.10þ/-5.28mm (p¼0.091) and to 24.10þ/-5.28mm
(p ¼0.091). Systolic velocity (S’) at lateral tricuspid annulus increased
from 12.80þ/-3.76cm to 14.90þ/-3.98cm (p¼0.004) and to 14.80þ/-
3.79cm (p¼0.015) then to 15.60þ/-3.92cm (p¼0.001). Tei index
decreased from 0.359þ/-0.222 to 0.207þ/-0.095 (p¼0.026) and to
0.203þ/-0.089 (p¼0.024) then to 0.201þ/-0.086 (p¼0.014). Myocar-
dial acceleration during isovolumic contraction (IVA) increased from
0.410þ/-0.106 m/s2 (p¼0.027) to 0.568þ/-0.256 m/s2 and to 0.570þ/-
0.218 m/s2 (p¼0.010) then to 0.615þ/-0.231 m/s2 (p¼0.003) respec-
tively at baseline, 24h, one month and three months after PTMC.
There was no signiﬁcant fraction area change and dp/dt ratio of the
right ventricle immediately and at mid term after PTMC.
CONCLUSIONS We suggest that there is an immediate improvement
of right ventricular systolic function after PTMC that is maintained at
mid term follow-up. Also the fact that this tendency was conﬁrmed by
using echocardiographic parameters those are loading dependent
such TAPSE and others less loading dependent such IVA suggest that
those improvements could be independent from loading conditions.
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BACKGROUND Right ventricular dysfunction (RVdisf) is predictor of
poor outcome in patients with heart failure and valvular disease. The
aim of this study was to evaluate the impact and the evolution of
RVdisf in patients with moderate-severe functional mitral regurgita-
tion (FMR) after MitraClip.
METHODS From October 2008 to July 2014, 60 consecutive high
surgical risk patients were treated and stratiﬁed into two groups:
RVdysf-group (TAPSE <16 mm and/or S’TDS <10 cm/sec, 21 patients)
and No-RVdysf-group (38 patients).
RESULTS The overall mean age was 738 (83% male). Ischemic FMR
etiology was present in 67%. Mean LVEF was 3010. Between the two
groups the only signiﬁcant differences was in presence of stroke, ICD
and use of aldosterone-antagonist higher in RVdysf group. Acute
procedural success was achieved in 90%. At 6-month echocardio-
graphic follow-up signiﬁcant improvement of RV function was
observed in all patients and was driven by only the results of patients
with RVdysf (TAPSE 153.0 vs. 194.5, p¼0.007; S’ TDI 71.2 vs.
112.8, p<0.0001; baseline vs. 6-month, respectively). Overall mean
follow-up was 565310 days. Mean improvement in 6-MWT was 116 m
(signiﬁcant in both groups).
CONCLUSIONS This observational study shows that patients with
RVdysf and FMR have signiﬁcant improvement of RV function after
MitraClip procedure. The presence of RVdysf was not predictor of
unfavorable clinical outcome.CATEGORIES STRUCTURAL: Valvular Disease: Mitral
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BACKGROUND The risk of surgical mitral valve replacement in pa-
tients with severe mitral annular calciﬁcation (MAC) is very high due
to comorbidities and technical challenges related to calcium burden,
precluding surgery in many patients. There are few isolated reports of
successful transcatheter mitral valve replacement (TMVR) with
balloon expandable valves in this patient population. We report the
ﬁrst large analysis from a global registry of TMVR in MAC.
METHODS 44 patients in 17 centers from 8 different countries un-
derwent TMVR with the compassionate use of SAPIEN (Edwards
Lifesciences, Irvine, CA) valves between September of 2012 and April
of 2015.
RESULTS The mean age was 74 years (range 39-94), 71% were fe-
males, mean STS score 14.6% (range 1-29%). Most patients (91%) had
mitral stenosis and 9% mitral regurgitation. The average mean
gradient was 12 mmHg, mean area 1.04 cm2. The SAPIEN valve was
used in 11%, SAPIEN XT in 71% and SAPIEN 3 in 18% (23mm¼4.5%,
26 mm¼43.5%, 29mm¼52%). The delivery approach was transatrial in
11%, transapical in 41%, and transeptal in 48%. The valve was
implanted without embolization in 41 (93%) patients, 6 (14%) required
a second valve-in-valve (migration¼2, regurgitation¼4), and 5 (11%)
had left ventricular tract obstruction (LVOTO) with hemodynamic
B292 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5compromise. The mean gradient post-procedure was 4.3 mmHg,
paravalvular regurgitation was mild or absent in all. The 30 day
mortality was 34%, cardiac¼13.6% (LVOTO, LV perforation, AV block,
MI) and non-cardiac¼20.4% (multiorgan failure, pneumonia,
bleeding, stroke). NYHA class at baseline was 3 or 4 in 98%. At follow-
up (mean 5 months, range 1-32), all survivors were in NYHA class I or II
at 30 days (n¼12) and at 1 year (n¼6).
CONCLUSIONS This ﬁrst large analysis of TMVR with balloon
expandable valves in patients with severe MAC reveals that the
procedure is feasible but may be associated with signiﬁcant adverse
events. This strategy might be an alternative for selected inoperable
patients without other treatment options. Studies are needed to
determine how patients should be screened to identify optimal
candidates for this challenging procedure and improve clinical
outcomes.
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BACKGROUND Redo surgery for degenerated mitral valve bio-
prostheses or failing surgical mitral rings may be high risk in-
terventions, especially in elderly patients with comorbidities.
Transcatheter mitral valve-in-valve implantation procedures are
constantly evolving.
METHODS Between November 2010 and June 2015, 22 patients (71.2 
13.4 years; 7 men [31.8%]; 16 in NYHA class III, 6 in NYHA class IV; log.
EuroScore 33.8  17.1%; STS score 11.5  9.2%) underwent a trans-
catheter procedure due to a degenerated bioprosthesis (n¼14) or a
failing surgical ring (n¼8) in the mitral position. Using the SAPIEN
(n¼1), SAPIEN XT (n¼15) and SAPIEN 3 (n¼6) prostheses, access routes
were transapical (n¼13), transfemoral-transseptal (n¼8) and trans-
jugular-transseptal (n¼1). Indications for the interventions were
mitral stenosis (n¼7) and mitral regurgitation (n¼15).
RESULTS The mean time interval between index surgery and the
transcatheter procedure was 8.8  4.6 years. Procedural success was
100%. There was one major vascular complication (4.5%) and one
acute kidney injury (4.5%) after the procedure. Three patients (13.6%)
had a stroke. New pacemaker implantation was not required in any
patient. The degree of post-interventional mitral regurgitation was
none or mild in all cases but one who had mild-to-moderate para-
valvular regurgitation. Final mean transmitral pressure gradient was
6.2  2.1 mmHg. Haemodynamically, signiﬁcant reductions in capil-
lary wedge and left atrial pressure were observed immediately after
the procedure (24.3  8.6 mmHg vs. 18.1  6.0 mmHg [p < 0.05] and
22.9  8.3 mmHg vs. 13.8  5.9 mmHg [p < 0.05], respectively). Thirty-
day mortality was 9.1% (2/18). One patient who was treated as a life-
saving measure in a cardiogenic shock situation with multiple organ
dysfunction syndrome died 5 days after the procedure due to septic
shock, the second patient died 10 days after the procedure due to
pneumonia (patient refused an intubation and mechanical
ventilation).
CONCLUSIONS Our initial experience showed that transcatheter im-
plantation of aortic-valve prostheses for degenerated bioprostheses or
surgical rings in the mitral position is feasible and safe, regardless of
valve type or access route. Hemodynamics were acutely improved.
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BACKGROUND Transcatheter percutaneous mitral valve repair with
the MitraClip procedure continues to be utilized in higher risk patient
groups and more complex mitral valve anatomy. Patients with chronic
kidney disease (CKD) represent a high risk subset of patients generally
excluded from randomized clinical trials. Patients with CKD were
excluded in the initial randomized clinical trials (EVEREST I/II) eval-
uating the MitraClip procedure. The aim of the current multi-center
registry is to determine acute and short-term MitraClip procedural
outcomes in patients with CKD.
METHODS Patients are being enrolled from 4 clinical sites using the
MitraClip in a commercial manner. To date, 80 patients with severe (3-
4þ) mitral regurgitation (MR) were included in this analysis. CKD was
deﬁned as a GFR less than 40 ml/min as estimated by the Cockcroft-
Gault formula. Acute procedural success was deﬁned as implantation
of at least one MitraClip with a reduction of MR severity to 2þ or less.
The acute and short term functional class and NYHA were then
analyzed.
RESULTS Thirty-nine patients were included in the CKD group, of
which four of these were on hemodialysis. Mean creatinine was 1.1 
0.07 in patients with preserved renal function versus 2.4  0.3 mg/dl
in the patient’s with CKD. Patients with CKD had more history of
coronary artery disease and lower hemoglobin levels. There were no
signiﬁcant differences in other baseline demographics in the two
groups (Table 1). Acute procedural success was achieved in all
patients. On average there were 1.7  0.12 clips implanted in the
non-CKD vs 1.6  0.09 clips in the CKD group (p ¼ 0.57). The
discharge trans-mitral gradient did not differ between the groups
(3.9  0.4 vs 4.0  1.1 mmHg, p ¼ 0.72). There was no change in
creatinine from pre- to post-procedure in the two groups. At one
month follow-up, there was no difference in NYHA class and MR
grade between the two groups.
CONCLUSIONS In this real-world registry, patients with existing renal
dysfunction had acute and short-term outcomes that were similar to
patients who did not have impaired renal function. In this ongoing
registry, further analysis will be performed evaluating procedural
differences, complications, mid-term outcomes, and survival in pa-
tients with and without CKD.No CKD
n[41CKD
n[39 P ValueAge (yr) 72  1.5 77  2.1 0.1
Male (%) 24 (59) 22 (56) 0.85HTN (%) 28 (70) 30 (77) 0.49DM (%) 9 (23) 15 (40) 0.12CAD (%) 19 (46) 29 (74) 0.01On HD (%) 0 (0) 4 (11) 0.04EF >55% (%) 26 (63) 21 (54) 0.39Creatinine (mg/dL) 1.1  0.07 2.4  0.3 0.0001
Hemoglobin (g/dl) 13.0  0.2 11.5  0.2 0.00001
No of Clips 1.7  0.12 1.6  0.09 0.44
Discharge TMG
(mmHg)3.9  0.4 4  1.1 0.72OneMo NYHA > III (%) 3 (7) 2 (5) 0.69One Mo MR >[ 3D
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